Views 168
Citations 0
Aug 2012

Is It Too Early to Predict the Failure of Natalizumab in NMO?

Author Affiliations

Author Affiliations: Department of Neurology, Cleveland Clinic Florida, Weston, Florida.

Arch Neurol. 2012;69(8):1085-1086. doi:10.1001/archneurol.2012.1138

We read with interest the article by Kleiter et al1 on the role of natalizumab in the treatment of neuromyelitis optica (NMO). The authors reported a case series in which patients who were previously diagnosed as having multiple sclerosis (MS) were eventually diagnosed as having NMO. They were treated with natalizumab and showed not only persistent disease activity but also had recurrent relapses within 4 months of starting therapy.1